REPORT HIGHLIGHTS

Resource Allocation Trends by Drug Companies

Quantitative Segment Analysis of Preclinical and Clinical Budget Trends

CRO Utilization Outlook by Large and Small Pharmaceutical / Biopharmaceutical Companies

US and EU R&D Spending & CRO Utilization Differences

Insights from Top-25, Global Pharmaceutical / Biopharmaceutical Companies

Quotes from Directors / Senior Directors, Vice Presidents of R&D and Principal Scientists, in Preclinical Development, Clinical Development, & Contracting and Outsourcing Groups

NEW SYNDICATED REPORT

2009 R&D BUDGET TRENDS & CRO UTILIZATION – WHERE ARE THE R&D DOLLARS GOING?

R&D spending is shifting – and to where may surprise you. According to new research conducted by Life Science Strategy Group with nearly 115 R&D decision makers at leading pharmaceutical and biotechnology companies in the US, Europe and Asia Pacific regions, approximately 50% of respondents anticipate shifts in R&D budgets from preclinical to clinical development over the next 2–3 years. Less than 10% of respondents report R&D budget shifts from clinical to preclinical development.

While budgeting shifts are taking place, respondents report future, continued investment in both preclinical and clinical R&D budgets. Within both preclinical and clinical development, respondents anticipate positive annual budget growth over the next 2–3 years. Rationale for the shifts reflects a variety of reasons that include maturing pipelines and corporate strategies to maximize near–term revenue and improve access to equity investment.

These reported trends are further reinforced by strategies to maximize the value of R&D spend. In particular, respondents state their companies are placing greater scrutiny on R&D spending. While many respondents report continued reductions in internal resources and capabilities, it is likely that CROs will be a key beneficiary, with pharmaceutical and biotechnology respondents indicating continued growth in utilization of CROs for both preclinical and clinical development.

You can learn about these and more key findings, gain in–depth insight into specific areas of budget growth and estimated rates, as well as a better understanding of specific areas of increased CRO utilization in LSSG´s Q1 2009 Life Science R&D Spending Trends & CRO Utilization Report.

To download complimentary sample pages or to purchase the full comprehensive report, please visit www.lifesciencestrategy.com/publications.

Copyright © 2009. Life Science Strategy Group, LLC.